# EDGAR Filing Document

**Accession Number:** 0001742927
**File Stem:** 0001493152-26-012362
**Filing Date:** 2026-3
**Character Count:** 8135
**Document Hash:** a446478c3d70ac5b6260550ea222736a
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001493152-26-012362.hdr.sgml**: 20260324

**ACCESSION NUMBER**: 0001493152-26-012362

**CONFORMED SUBMISSION TYPE**: SCHEDULE 13D/A

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20260324

**DATE AS OF CHANGE**: 20260324

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** REVIVA PHARMACEUTICALS HOLDINGS, INC.
- **CENTRAL INDEX KEY:** 0001742927
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D/A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-90624
- **FILM NUMBER:** 26786398

**BUSINESS ADDRESS:**
- **STREET 1:** 10080 N WOLFE ROAD
- **STREET 2:** SUITE SW3-200
- **CITY:** CUPERTINO
- **STATE:** CA
- **ZIP:** 95014
- **BUSINESS PHONE:** 4085018881

**MAIL ADDRESS:**
- **STREET 1:** 10080 N WOLFE ROAD
- **STREET 2:** SUITE SW3-200
- **CITY:** CUPERTINO
- **STATE:** CA
- **ZIP:** 95014

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Tenzing Acquisition Corp.
- **DATE OF NAME CHANGE:** 20180606
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** SAXENA PARAG
- **CENTRAL INDEX KEY:** 0001015823

**ORGANIZATION NAME:**
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D/A

**MAIL ADDRESS:**
- **STREET 1:** 250 WEST 55TH STREET, SUITE 13D
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10019

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## SCHEDULE 13D

### Under the Securities Exchange Act of 1934

**(Amendment No. 13)**

**REVIVA PHARMACEUTICALS HOLDINGS, INC.**

*(Name of Issuer)*

**Common Stock, $0.0001 par value**

*(Title of Class of Securities)*

**—**

*(CUSIP Number)*

**Parag Saxena**<br>Vedanta Management, L.P.,<br>250 West 55th Street, Ste 16C<br>New York NY 10019<br>212-710-5220

*(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)*

**03/20/2026**

*(Date of Event Which Requires Filing of this Statement)*

| **CUSIP No.** | **—** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Parag Saxena** | Name of reporting person<br>**Parag Saxena** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**AF** | Source of funds (See Instructions)<br>**AF** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**K7** | Citizenship or place of organization<br>**K7** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**45047.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**318233.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**45047.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**318233.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**363280.00** | Aggregate amount beneficially owned by each reporting person<br>**363280.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**2.8%** | Percent of class represented by amount in Row (11)<br>**2.8%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**IN** | Type of Reporting Person (See Instructions)<br>**IN** | |

---

**Comment for Reporting Person:** See Item 5 for additional information.

**Item 1. Security and Issuer**

**(a) Title of Class of Securities:**
Common Stock, $0.0001 par value

**(b) Name of Issuer:**
REVIVA PHARMACEUTICALS HOLDINGS, INC.

**(c) Address of Issuer's Principal Executive Offices:**
Vedanta Management, L.P., 250 West 55th Street, Ste 16C, New York, NY, 10019

This Amendment No. 13 to Schedule 13D (this "Amendment No. 13"), filed on behalf of Parag Saxena (the "Reporting Person"), amends and supplements the Schedule 13D filed with the Securities and Exchange Commission (the "SEC") on September 4, 2018, as amended and supplemented by Amendment No. 1, Amendment No. 2 and Amendment No. 3 on January 19, 2021, Amendment No. 4 on June 3, 2021, Amendment No. 5 on September 12, 2022, Amendment No. 6 on November 30, 2023, Amendment No. 7 on May 31, 2024, Amendment No. 8 on August 23, 2024, Amendment No. 9 on January 31, 2025, Amendment No. 10 on July 1, 2025, Amendment No. 11 on September 24, 2025, and Amendment No. 12 on December 22, 2025 (as amended, the "Schedule 13D"). Except as specifically provided herein, this Amendment No. 13 does not modify or amend any of the information previously reported in the Schedule 13D. Capitalized terms used and not otherwise defined herein shall have the meanings ascribed to such terms in the Schedule 13D.

**Item 5. Interest in Securities of the Issuer**

**(a)**
The information set forth in rows 11 and 13 of the cover page to this Amendment No. 13 are incorporated by reference into this Item 5. The percentage set forth in row 13 of the cover page is based on 12,810,377 outstanding shares of common stock, par value $0.0001 per share ("Common Stock"), of Reviva Pharmaceuticals Holdings, Inc., a Delaware corporation (the "Issuer"), as of March 20, 2026, as reported directly by the Issuer to the Reporting Person.

**(b)**
The information set forth in rows 7 through 10 of the cover pages to this Amendment No. 13 is incorporated by reference. The 363,280 shares of Common Stock reported as beneficially owned on this Amendment No. 13 by Mr. Saxena consist of the following: (i) 45,047 shares of Common Stock held directly, (ii) 46,550 shares of Common Stock held by Vedanta Associates-R, (iii) 19,950 shares of Common Stock held by Beta Operators, (iv) 4,977 shares of Common Stock held by Vedanta Associates, (v) 60,605 shares of Common Stock underlying warrants held by Vedanta Associates-R, (vi) 58,442 shares of Common Stock underlying warrants held by Beta Operators, (vii) 29,269 shares of Common Stock underlying warrants held by Vedanta R2, (viii) 25,692 shares of Common Stock underlying pre-funded warrants held by Vedanta Associates-R, (ix) 43,479 shares of Common Stock underlying pre-funded warrants held by Beta Operators, (x) 29,269 shares of Common Stock underlying pre-funded warrants held by Vedanta R2, and (xi) 1,480 underlying options that are fully vested as of March 24, 2026 (the "Filing Date"). As a result, Mr. Saxena is deemed to beneficially own approximately 2.8% of the outstanding shares of Common Stock of the Issuer as of the Filing Date. The securities beneficially owned by Mr. Saxena exclude 410 shares underlying options that are unvested as of 60 days of the Filing Date. In accordance with Rule 13d-3, the beneficial ownership percentage for the Reporting Person assumes that the warrants and options that can be exercised within 60 days of the Filing Date, if any, held by the Reporting Person have been exercised, and that no other warrants or options have been exercised.

**(c)**
The Reporting Person has not effected any transactions during the past sixty (60) days from the date of this filing in any securities of the Issuer.

### SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Parag Saxena

**Signature:** /s/ Parag Saxena

**Name/Title:** Parag Saxena/Individual

**Date:** 03/24/2026